Abstract 103P
Background
Texture analysis is used to assess the homogeneous or nonhomogenous information of the selected regions, and provides many quantitative and semiquantitative parameters that are able to closely reflect the characteristics of cancer lesions. This study was designed to estimate the clinical significance of the contrast-enhanced computed tomograpgy (CT) textural features for prediction of survival in colorectal cancer (CRC) patients receiving targeted therapy (bevacizumab and cetuximab).
Methods
The LifeX software was used to extract the textural parameters of the tumor lesions in the contrast-enhanced CT. Univariate and multivariate analyses using the Cox proportional hazards model were performed to assess the prognostic value of textural parameters.
Results
Eighty CRC patients receiving targeted therapy (bevacizumab 42; cetuximab 38) were included. In the multivariate analysis, 8 textural parameters were revealed to be independent predictors (p < 0.05) of progression-free survival (PFS) and overall survival (OS), including Skewness, Kurtosis, Homogeneity, Energy and Entropy of Gray-level co-occurrence matrix (GLCM), Long-run emphasis (LRE), Long-run high gray-level emphasis (LRHGE), and Contrast. Furthermore, Sphericity, Compacity, Long-run low gray-level emphasis (LRLGE), Low gray-level zone emphasis (LGZE) and Short-zone low gray-level emphasis (SZLGE) were show to be significantly associated with PFS, while Entropy-Histogram and Energy-Histogram, Dissimilarty, Short-run emphasis (SRE), Short-run low gray-level emphasis (SRLGE), Run percentage (RP), Long-zone emphasis (LZE), Long-zone low gray-level emphasis (LZLGE) and Long-zone high gray-level emphasis (LZHGE) were significantly associated with OS.
Conclusions
In conclusion, our study provides preliminary evidences that several radiomic parameters of tumor lesions derived from CT images were prognostic factors and predictive markers for CRC patients who are candidates for targeted therapy (bevacizumab and cetuximab).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
185P - Evaluation of the effect of cholesorption on the concentration of TNF-α in the serum of the blood in tumours of the biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
186P - Efficacy and safety of sorafenib following hepatic resection in patients with hepatocellular carcinoma: A meta-analysis
Presenter: Yang Yuan
Session: Poster display session
Resources:
Abstract
187P - Correlation between spleenic dose and grade of hematological toxicity in chemoradiation of stomach
Presenter: Umesh Velu
Session: Poster display session
Resources:
Abstract
188P - Survival and prognostic factors in cholangiocarcinoma: A single-center experience
Presenter: Sonngwit Payapwattanawong
Session: Poster display session
Resources:
Abstract
189P - Stereotactic body radiotherapy in primary hepatocellular carcinoma and oligometastatis to liver: A single Institution experience
Presenter: Sayan Paul
Session: Poster display session
Resources:
Abstract
190P - Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
Presenter: Yusuke Nagata
Session: Poster display session
Resources:
Abstract
191P - Assessment of efficacy and safety of sorafenib versus no treatment in Egyptian hepatocellular carcinoma patients
Presenter: Noha El Baghdady
Session: Poster display session
Resources:
Abstract
192P - Clinical importance of the determination of interleukin-6 in bile and blood in tumours of biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
193P - Metastatic carcinoma gall bladder: A clinicoepidemiological profile of Indian patients
Presenter: Anvesh Rathore
Session: Poster display session
Resources:
Abstract
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract